About this Research Topic
Improving the basic science understanding of SE will facilitate essential clinical trials. One can envision such trials to include device and compound-based technological interventions directed at aborting the seizure activity and improving clinical outcomes. Benzodiazepines remain one of the cornerstones of treatment, and studies are underway to study new delivery options, including intranasal, buccal and intramuscular midazolam, in addition to rectal diazepam, with the goal of aborting the seizure activity outside the hospitals, as rapidly as possible. Approved and off-label anticonvulsants, such as phenytoin, phenobarbital, valproate, topiramate, levetiracetam, lacosamide, steroids, immunosuppressants and neuroprotective compounds, have also shown some efficacy at treating SE. However, substantial challenges remain in optimally treating SE and minimizing the short- and long-term complications. Such challenges can be overcome by innovative approaches targeting the basic mechanisms of neuronal excitability, glia, neuronal death, neuroplasticity, oxidative stress, inflammation and neuroinflammation.
In this Research Topic, we aim to feature original and review articles that provide insight into the pathophysiology, clinical presentation, treatment, recent advances and future directions in the management of SE, with the goal of providing an in-depth view and advancing the field to improve management of SE.
Keywords: seizure, status epilepticus
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.